Australia markets open in 1 hour 32 minutes

PYC Therapeutics Limited (PYC.AX)

ASX - ASX Delayed price. Currency in AUD
Add to watchlist
0.10000.0000 (0.00%)
At close: 04:10PM AEST
Full screen
Previous close0.1000
Open0.1050
Bid0.1050 x 42340100
Ask0.1000 x 21464600
Day's range0.1000 - 0.1050
52-week range0.0520 - 0.1200
Volume6,752,260
Avg. volume2,571,944
Market cap466.608M
Beta (5Y monthly)0.60
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • PR Newswire

    PYC'S FOURTH DRUG CANDIDATE HAS DISEASE-MODIFYING POTENTIAL IN POLYCYSTIC KIDNEY DISEASE

    PYC Therapeutics today announces the results of a study conducted in human 3-dimensional models derived from patients with end-stage renal failure due to Autosomal Dominant Polycystic Kidney Disease (PKD). The results demonstrate that an investigational drug candidate designed by PYC (known as PYC-003) to address this disease at its root cause is effective. These 3D patient-derived cyst models represent the 'gold-standard' pre-clinical assay for evaluating drug candidates in this indication[8].

  • PR Newswire

    US FDA DESIGNATES PYC'S LEAD AS A FAST TRACK DEVELOPMENT PROGRAM

    PYC Therapeutics Limited (ASX:PYC) today announces that the VP-001 program, the first investigational drug candidate designed to address Retinitis Pigmentosa type 11 (RP11) to progress to human trials, has received Fast Track designation from the US Food and Drug Administration (FDA).